T. Rowe Price Associates
BLUE

T. Rowe Price Associates’s bluebird bio BLUE Stock Holding History

T. Rowe Price Associates’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,171
Closed -$33K – 3019
2024
Q3 		$33K Buy
3,171
+435
+16% +$7.23K ﹤0.01% 2967
2024
Q2 		$54K Hold
2,736
– – ﹤0.01% 2844
2024
Q1 		$71K Buy
2,736
+1,456
+114% +$37.3K ﹤0.01% 2831
2023
Q4 		$36K Buy
1,280
+120
+10% +$7.32K ﹤0.01% 2843
2023
Q3 		$71K Sell
1,160
-1,006
-46% -$70.7K ﹤0.01% 2723
2023
Q2 		$143K Buy
2,166
+462
+27% +$33.8K ﹤0.01% 2617
2023
Q1 		$109K Buy
1,704
+247
+17% +$28.2K ﹤0.01% 2666
2022
Q4 		$202K Buy
1,457
+46
+3% +$6.48K ﹤0.01% 2528
2022
Q3 		$179K Buy
1,411
+351
+33% +$39.7K ﹤0.01% 2584
2022
Q2 		$88K Buy
1,060
+26
+3% +$2.02K ﹤0.01% 2780
2022
Q1 		$100K Buy
1,034
+75
+8% +$9.9K ﹤0.01% 2844
2021
Q4 		$192K Sell
959
-1,222
-56% -$288K ﹤0.01% 2768
2021
Q3 		$540K Buy
2,181
+4
+0.2% +$1.14K ﹤0.01% 2350
2021
Q2 		$902K Sell
2,177
-71,305
-97% -$28.2M ﹤0.01% 2109
2021
Q1 		$28.7M Sell
73,482
-6,329
-8% -$3.12M ﹤0.01% 1182
2020
Q4 		$44.7M Buy
79,811
+5,436
+7% +$3.45M ﹤0.01% 1000
2020
Q3 		$52M Sell
74,375
-36,842
-33% -$28.7M 0.01% 858
2020
Q2 		$87.9M Buy
111,217
+10,280
+10% +$7.75M 0.01% 672
2020
Q1 		$60.1M Sell
100,937
-27,282
-21% -$26.6M 0.01% 721
2019
Q4 		$146M Buy
128,219
+26,544
+26% +$28.9M 0.02% 553
2019
Q3 		$121M Sell
101,675
-8,008
-7% -$12.2M 0.02% 569
2019
Q2 		$181M Sell
109,683
-8,835
-7% -$15.3M 0.03% 488
2019
Q1 		$242M Buy
118,518
+20,355
+21% +$35.8M 0.04% 417
2018
Q4 		$126M Sell
98,163
-106,955
-52% -$164M 0.02% 547
2018
Q3 		$388M Sell
205,118
-12,979
-6% -$26.8M 0.06% 325
2018
Q2 		$443M Sell
218,097
-1,709
-0.8% -$3.9M 0.07% 282
2018
Q1 		$486M Sell
219,806
-812
-0.4% -$2.07M 0.08% 261
2017
Q4 		$509M Buy
220,618
+9,350
+4% +$19M 0.08% 249
2017
Q3 		$376M Sell
211,268
-14,038
-6% -$19.6M 0.06% 313
2017
Q2 		$307M Sell
225,306
-12,227
-5% -$14.8M 0.06% 344
2017
Q1 		$280M Sell
237,533
-16,313
-6% -$16.6M 0.05% 354
2016
Q4 		$203M Sell
253,846
-5,994
-2% -$4.76M 0.04% 420
2016
Q3 		$228M Buy
259,840
+71,134
+38% +$51.5M 0.05% 392
2016
Q2 		$106M Buy
188,706
+21,903
+13% +$12.4M 0.02% 549
2016
Q1 		$91.8M Buy
166,803
+11,994
+8% +$7.37M 0.02% 579
2015
Q4 		$129M Buy
154,809
+13,504
+10% +$13.5M 0.03% 494
2015
Q3 		$157M Buy
141,305
+3,021
+2% +$5.51M 0.03% 462
2015
Q2 		$302M Sell
138,284
-10,038
-7% -$20.4M 0.06% 340
2015
Q1 		$232M Buy
148,322
+31,214
+27% +$41.2M 0.05% 403
2014
Q4 		$139M Buy
117,108
+34,715
+42% +$23.2M 0.03% 520
2014
Q3 		$38.3M Buy
+82,393
New +$38M 0.01% 918
2014
Q2 		– Sell
-13,787
Closed -$4.06M – 2534
2014
Q1 		$4.06M Sell
13,787
-23,548
-63% -$7.13M ﹤0.01% 1459
2013
Q4 		$10.1M Buy
+37,335
New +$10.4M ﹤0.01% 1281

Other funds holding BLUE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

T. Rowe Price Associates's BLUE Position: Q4 2024 in Review

T. Rowe Price Associates sold out of bluebird bio (BLUE) in Q4 2024, closing a stake of 3,171 shares — an estimated $33K sold.

T. Rowe Price Associates first reported a position in BLUE in Q4 2013 and held it in 43 quarters. The position peaked at $509M in Q4 2017. 83 funds tracked by Wall St. Rank hold BLUE as of Q4 2024.

  • T. Rowe Price Associates reported no remaining bluebird bio position as of Q4 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 3,171 bluebird bio shares in Q4 2024, an estimated $33K.
  • T. Rowe Price Associates first reported a position in bluebird bio in Q4 2013 and held it in 43 quarters.
  • T. Rowe Price Associates's bluebird bio position peaked at $509M in Q4 2017.
  • 83 funds tracked by Wall St. Rank held bluebird bio as of Q4 2024.

Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.